INKT

+ Watchlist + Portfolio

MiNK Therapeutics, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $11.36
52-Week Range: $8.48 – $16.98
Market Cap: $59.30M
P/E (TTM): —
EPS (TTM): -2.37
Dividend Yield: —

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: —
Return on Assets: -129.34%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 1.23
Debt/Equity: —
Total Debt: $0.00
Free Cash Flow: $-5.25M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $50.49M

INKT Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$23.12M	$15.49M	$6.34M	$5.76M
Selling, General & Admin	$7.83M	$7.43M	$4.31M	$6.73M
Operating Expenses	$30.95M	$22.92M	$10.65M	$12.49M
Operating Income	-$30.95M	-$22.92M	-$10.65M	-$12.49M
EBITDA	-$30.83M	-$22.72M	-$10.43M	-$12.31M
Pretax Income	-$27.99M	-$22.46M	-$10.78M	-$12.49M
Net Income	-$27.99M	-$22.46M	-$10.78M	-$12.49M
Diluted EPS	-8.30	-6.54	-2.86	-2.93
Diluted Shares	3.37M	3.44M	3.77M	4.27M

INKT Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$19.64M	$3.37M	$4.58M	$13.36M
Current Assets	$20.40M	$3.60M	$4.99M	$13.85M
Total Assets	$21.47M	$4.55M	$5.72M	$14.24M
Current Liabilities	$12.68M	$11.40M	$6.96M	$13.03M
Long-Term Debt	—	—	$4.92M	—
Total Debt	—	—	$4.92M	$5.18M
Total Liabilities	$21.87M	$22.61M	$25.31M	$28.47M
Retained Earnings	-$110.94M	-$133.40M	-$144.18M	-$156.68M
Shareholders' Equity	-$401.30K	-$18.06M	-$19.59M	-$14.23M
Working Capital	$7.72M	-$7.80M	-$1.97M	$816.52K
Net Debt	—	—	$347.57K	—

INKT Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$18.87M	-$15.76M	-$9.56M	-$5.93M
Capital Expenditure	-$250.05K	-$73.56K	—	—
Free Cash Flow	-$19.12M	-$15.84M	-$9.56M	-$5.93M
Depreciation & Amortisation	$121.75K	$204.62K	$215.44K	$181.75K
Stock-Based Compensation	$3.03M	$3.86M	$1.81M	$2.67M
Investing Cash Flow	-$250.05K	-$73.56K	$0.00	—
Financing Cash Flow	-$155.60K	-$407.17K	$10.82M	$14.72M
Share Repurchases	-$157.19K	-$477.64K	$0.00	—
Net Change in Cash	-$19.27M	-$16.24M	$1.26M	$8.80M

INKT Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$1.26M	$1.84M	$1.14M	$1.51M	$1.20M
Selling, General & Admin	$1.27M	$1.85M	$1.85M	$1.76M	$1.68M
Operating Expenses	$2.53M	$3.69M	$2.99M	$3.28M	$2.88M
Operating Income	-$2.53M	-$3.69M	-$2.99M	-$3.28M	-$2.88M
EBITDA	-$2.48M	-$3.64M	-$2.95M	-$3.24M	-$2.85M
Pretax Income	-$2.77M	-$4.24M	-$2.89M	-$2.60M	-$2.74M
Net Income	-$2.77M	-$4.24M	-$2.89M	-$2.60M	-$2.74M
Diluted EPS	-0.70	-1.06	-0.65	—	-0.57
Diluted Shares	3.96M	3.98M	4.44M	—	4.80M

INKT Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$3.23M	$1.68M	$14.28M	$13.36M	$9.53M
Current Assets	$3.58M	$2.01M	$14.53M	$13.85M	$10.02M
Total Assets	$4.27M	$2.48M	$14.96M	$14.24M	$10.38M
Current Liabilities	$12.12M	$13.16M	$13.43M	$13.03M	$7.29M
Total Debt	$5.12M	$5.51M	$5.73M	$5.18M	—
Total Liabilities	$26.06M	$27.67M	$28.48M	$28.47M	$23.06M
Retained Earnings	-$146.95M	-$151.19M	-$154.07M	-$156.68M	-$159.42M
Shareholders' Equity	-$21.79M	-$25.19M	-$13.51M	-$14.23M	-$12.69M
Working Capital	-$8.54M	-$11.15M	$1.10M	$816.52K	$2.74M
Net Debt	$1.88M	$3.82M	—	—	—

INKT Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$1.34M	-$1.57M	-$941.35K	-$2.07M	-$1.73M
Free Cash Flow	-$1.34M	-$1.57M	-$941.35K	-$2.07M	-$1.73M
Depreciation & Amortisation	$50.77K	$48.76K	$43.65K	$38.56K	$36.07K
Stock-Based Compensation	$591.09K	$896.55K	$620.59K	$565.77K	$630.39K
Financing Cash Flow	$576.00	$540.00	$13.55M	$1.18M	-$2.10M
Net Change in Cash	-$1.34M	-$1.57M	$12.60M	-$898.62K	-$3.83M

Market Snapshot

About

MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other life-threatening illnesses. The company's approach harnesses the unique properties of iNKT cells, which can recognize and kill tumor cells while modulating the immune system. MiNK's lead product candidate targets various solid tumors and hematologic malignancies. The company is advancing multiple programs through clinical development with the goal of creating off-the-shelf cell therapies that can be used across broad patient populations without the need for patient-specific manufacturing.